Related Experiment Video

Updated: Sep 12, 2025

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy
03:52

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy

Published on: February 21, 2025

510

Getting to the heart of sarcopenia and cardiovascular disease

Pouya Nezafati1,2, Pankaj Saxena3, Jaishankar Raman3,4

  • 1Discipline of Biomedical Sciences and Molecular Biology, College of Medicine and Dentistry, Australian Institute of Tropical Medicine and Health, Centre for Molecular Therapeutics, James Cook University, Townsville, QLD 4811, Australia.

Aging
|August 7, 2025
PubMed

Insights

Sarcopenia and cardiovascular disease share mechanisms, suggesting treatments for one may benefit the other. This review covers sarcopenia screening, diagnosis, and its links to heart health.

Area of Science:

  • Gerontology
  • Cardiology
  • Muscle Physiology

Background:

  • Sarcopenia and cardiovascular disease (CVD) exhibit overlapping pathophysiological pathways.
  • Effective management of one condition may alleviate the burden of the other.

Purpose of the Study:

  • To review sarcopenia screening and diagnostic strategies, including biomarkers and imaging.
  • To explore the pathophysiological links between sarcopenia and CVD.
  • To evaluate sarcopenia's impact on cardiac surgery and discuss management.

Main Methods:

  • Literature review of screening tools, diagnostic guidelines, and imaging modalities for sarcopenia.
  • Analysis of studies investigating the association between sarcopenia and CVD.
  • Evaluation of sarcopenia's effects on cardiac surgery outcomes.

Main Results:

  • Biomarkers, clinical guidelines, and screening questionnaires are used for sarcopenia assessment.
  • Imaging modalities aid in the quantification of sarcopenia.
  • Shared mechanisms highlight potential for integrated management strategies.

Conclusions:

  • Understanding the link between sarcopenia and CVD is crucial for developing comprehensive treatment plans.
  • Early screening and diagnosis of sarcopenia can inform cardiovascular risk assessment.
  • Interventions targeting sarcopenia may improve outcomes in patients with or at risk of CVD, including those undergoing cardiac surgery.

Keywords:
cardiac surgerycardiovascular diseasediagnosissarcopeniascreening

More Related Videos

Segmentation and Linear Measurement for Body Composition Analysis using Slice-O-Matic and Horos13:35

Segmentation and Linear Measurement for Body Composition Analysis using Slice-O-Matic and Horos

Published on: March 21, 2021

10.7K
Author Spotlight: Assessing Surgical Frailty with Point-of-Care Ultrasound of Quadriceps Muscles04:00

Author Spotlight: Assessing Surgical Frailty with Point-of-Care Ultrasound of Quadriceps Muscles

Published on: July 26, 2024

664

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
57
Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
78
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
36
Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
805
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
41
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
48